Home/Biosimilar Atlas/Bevacizumab/Dr. Reddy's bevacizumab

Dr. Reddy's bevacizumab

Bevacizumab biosimilar developed by Dr. Reddy's Laboratories. Reference product Avastin.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Dr. Reddy's Laboratories · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOSep 2018permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
BevacizumabmoleculeDr. Reddy's Laboratoriesdeveloper1 of 7markets0trials behind it5other products, same developer7rival developers in its markets

About Dr. Reddy's bevacizumab

Dr. Reddy's received its bevacizumab permission in India in 2018, with a separate permission for the drug substance in 2022 and liver cancer added in 2026. It is one of the more complete Indian bevacizumab labels.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Dr. Reddy's Laboratories Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Sep 2018
Application or permission
MF/BIO/18/000025; drug substance MF/BIO/22/000030; additional indication MF/BIO/26/000076
Indications as licensed
Colorectal, NSCLC and other reference indications; hepatocellular carcinoma with atezolizumab added June 2026
Presentations
100 mg/4 mL and 400 mg/16 mL
Source
S014 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Dr. Reddy's bevacizumab holds an approval, these are the other bevacizumab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO7Biocon Biologics (Jobevne / Abevmy / Krabeva), CuraTeQ Biologics (CuraTeQ bevacizumab), Enzene Biosciences (Enzene Biosciences bevacizumab), Hetero (Hetero bevacizumab), Intas Pharmaceuticals (Intas bevacizumab), Reliance Life Sciences (Reliance Life Sciences bevacizumab), Zydus Lifesciences (Zydus bevacizumab)

Same developer, other molecules

Other biosimilars in the Atlas developed by Dr. Reddy's Laboratories: Dr. Reddy's darbepoetin alfa, Dr. Reddy's pegfilgrastim, Dr. Reddy's trastuzumab, Teriparatide Dr. Reddy's, Zimrixby / Ituxredi.

Chronology

Sources

All bevacizumab biosimilars

Planning bevacizumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.